254 results on '"Cox, Josephine H."'
Search Results
2. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
3. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
4. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
5. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
6. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men
7. Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy
8. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
9. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
10. Vaccines for The Prevention and Treatment of HIV Infection
11. A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172)
12. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition
13. Preparation of Clinical-Grade Recombinant Canarypox-Human Immunodeficiency Virus Vaccine-Loaded Human Dendritic Cells
14. Preliminary Evaluation of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen in Children with HIV-1 Infection
15. Antigen Presentation Requires Transport of MHC Class I Molecules from the Endoplasmic Reticulum
16. Correlation between Humoral Responses to Human Immunodeficiency Virus Type 1 Envelope and Disease Progression in Early-Stage Infection
17. Cross-Clade Cytotoxic T Cell Response to Human Immunodeficiency Virus Type 1 Proteins among HLA Disparate North Americans and Thais
18. Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials
19. Evaluation of natural killer cell activity
20. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus erotype 5 boost vaccine in HIV-uninfected east Africans (RV 172)
21. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I /II ALVAC-HIV /AIDSVAX ® B/E prime-boost HIV-1 vaccine trial in Thailand
22. A003 Protocol - A Phase 1, randomized, blinded, dose-escalation study of rAAV1-PG9DP recombinant AAV vector coding for PG9 antibody in healthy male adults
23. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development
24. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides
25. Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons
26. Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans
27. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
28. Multiplexed FluoroSpot for the Analysis of Dengue Virus– and Zika Virus–Specific and Cross-Reactive Memory B Cells
29. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop
30. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response
31. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
32. Performance of an IAVI-African Network of Clinical Research Laboratories in Standardized ELISpot and Peripheral Blood Mononuclear Cell Processing in Support of HIV Vaccine Clinical Trials
33. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
34. Adeno-Associated Virus Vectored Immunoprophylaxis to Prevent HIV: A Phase 1 Randomized Controlled Trial in Healthy Adults
35. Establishment and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope-Specific CD4⁺ T Lymphocyte Lines from HIV-1-Seropositive Patients
36. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
37. Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults
38. An influenza vaccine pill—can we swallow it?
39. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults
40. Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G (NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers
41. Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment
42. HIV-1-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC)
43. Evaluation of Natural Killer Cell Activity
44. Standardization and Validation Issues of the ELISPOT Assay
45. HIV-1-Specific Cytotoxic T-Cell Assays
46. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses
47. Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
48. Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults
49. Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
50. A DNA-Based Candidate HIV Vaccine Delivered via In Vivo Electroporation Induces CD4 Responses toward the α4β7-Binding V2 Loop of HIV gp120 in Healthy Volunteers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.